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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
AE 
AHRS 
Adverse events 
Auditory hallucinations ratings scale 
AMSTAR Assessing the quality of systematic reviews 
BAI 
BPRS 
BRAMES 
Beck Anxiety Inventory 
Brief psychiatry ratings scale 
Bech-Rafaelsen melancholia scale 
BCVA Best corrected visual activity 
BDI Becks depression index 
BMI Body mass index (kg/m
2
) 
CBT Cognitive behavioural  therapy 
CG Clinical guideline 
CGI-S Clinical global impression - severity 
DH Department of Health 
EMA European Medicines Agency 
EQ-5D EuroQol 5 dimensions 
FR 
GAF 
GARF 
GSDS 
Future research 
Global assessment of functioning scale 
Global assessment of relational functioning scale 
Groningen social disabilities scale 
HADS 
HoNOS 
Hospital anxiety and depression scale 
Health of the nation outcome scales 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
HUI3 
ICD-10 
Health Utility Index mark 3 
International statistical classification of diseases  W 10th revision 
MBCT 
MID 
Mindfulness-based cognitive therapy 
Minimally important clinical difference 
NCA National Clinical Audit 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
PANSS 
PR 
Positive and negative syndrome scale 
Potential recommendations 
PREM Patient Reported Experience Measure 
PROM(s) patient reported outcome measure(s) 
Q-LES-Q 
QoL 
R&D 
Quality of life enjoyment and satisfaction questionnaire 
Quality of life 
Research and development 
RCT Randomised controlled trial 
SF-6D 
SF-12 
SF-36 
SCL-90-R 
SOFAS 
Short form 6D 
Short Form 12 item 
Short form 36 item 
Symptom checklist 90 
Social and occupational functioning 
SRM Standardised response mean 
STA Single technology assessment 
TTO Time trade off 
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UK United Kingdom 
VAS Visual analogue scale 
WHOQOL-BREF WHO quality of life - BREF 
WP Work package 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (R&D Division) to prepare a programme of research to support 
the appropriateness of, and use of, patient reported outcome measures (PROMs) collected for the 
National Clinical Audit (NCA).  The EEPRU programme was informed by a R&D template prepared by 
Simon Bennett, Steve Fairman and Keith Willett at NHS England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the National Health Service (NHS), 2) 
compare the cost-effectiveness of alternative providers in delivering the specific services (i.e. linking 
outcomes and resource use), and 3) assess the cost-effectiveness of alternative interventions and 
other changes in the NHS.  The intention is to introduce PROMs across a range of conditions over the 
next 3 years commencing with 13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Department of Health (DH) (8
th
 November 2013).  The current document 
provides details on the objectives, methodology and results for Work Package 1 (WP1): to determine 
what PROMS should be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EuroQoL 5 dimensions (EQ-5D) is appropriate in the 13 health 
conditions specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature and the specific review objectives 
and methodologies are described in detail in the following sections. 
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3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appriasials were 
reviewed and data requirements were compared with variables currently collected in the 
schizophrenia  audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to an alternative condition specific or generic 
measure). In case ď ?ƚŚĞŵĞĂƐƵƌĞŵĂǇďĞĐŽŵƉůĞƚĞĚďǇŵƵůƚŝƉůĞƉĞŽƉůĞ  ?ƉƌŽǆŝĞƐ ?ŽŶƚŚĞƉĂƚŝĞŶƚ ?Ɛ
behalf and their responses compared with those of the patient. Where the outcome measure is 
specifically designed for self-report by patients, this test of reliability may be expected to produce 
less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
8 
 
a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
The main sources that were searched for information and recommendations relating to condition-
specific or generic measures were: 
x Recommendations made in the Oxford set of reviews (http://phi.uhce.ox.ac.uk/) 
x The DH PROMS programme 
x Recommendations of the Royal Colleges  
x European medicines agency (EMA) research guidelines 
x Research charity websites.  
The recommendations made in these sources were presented and discussed narratively.  
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing HTAs were reviewed alongside the variables currently collected in the NCA to determine 
if clinical or PROM data routinely collected in the NCAs would suffice to address questions of cost-
9 
 
effectiveness, and to identify any gaps in the evidence that would be required to compare providers, 
or the cost-effectiveness of interventions or policies. 
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4. RESULTS FOR SCHIZOPHRENIA 
4.1 Evidence of appropriatness of EQ-5D in schizophrenia (WP1.1) 
4.1.1 Selection of systematic review 
Only one systematic review on schizophrenia was identified. (4) 
 
4.1.2 Structured abstract for Papaioannou et al 2011 (4) 
Purpose of review 
The review aimed to investigate the construct validity and responsiveness of four generic health 
status measures, including two generic HRQL profile measures (Short-form 36 item (SF-36), Short-
form 12 item (SF-12)), and two preference-based HRQL measures (SF-6D, EQ-5D) in schizophrenia.  
 
Methods of review 
Search and study selection: Ten databases were searched from inception: Cochrane Database of 
Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economics and Evaluations 
Database, Health Technology Database, Database of Abstracts of Reviews of Effects, MEDLINE, 
PreMEDLINE, CINAHL, EMBASE, and Web of Science.  Electronic searches were conducted in August 
2009. Two sets of search strategies combined terms for each of the four health related quality of life 
(HRQoL) measures with terms for each of a number of health conditions, of which schizophrenia was 
one. Only results for schizophrenia were reported in this paper. The full search strategies were not 
reported.  
 
Inclusion criteria: Studies were included in the review if they satisfied the following criteria: they 
contained HRQoL data as measured by one of four HRQoL instruments, namely SF-36, SF-12, SF-6D, 
or EQ- ? ? ĂĚƵůƚƐ A? ? ? ǇĞĂƌƐ ŽůĚ ǁŝƚŚ ƐĐŚŝǌŽƉŚƌĞŶŝĂ Žƌ ƐĐŚŝǌŽƉŚƌĞŶŝĂ-related disorders, e.g. 
schizophreniform disorder or schizoaffective disorder. Data relating to HRQoL had to be from 
descriptive systems (their items or dimensions), health state utility values generated by the EQ-5D or 
SF-6D, or the EQ-5D visual analogue scale (VAS). Studies had to contain data from the HRQoL 
instrument that allowed measurement of construct validity (convergent or known groups), or 
responsiveness (effect sizes, standardised response means, or correlation with change scores on 
symptom measures).  
 
Exclusion criteria: Studies were excluded from the review if the study population were primarily 
individuals with alcohol and/or drug dependency with comorbid schizophrenia or schizophrenia-
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related disorders. Studies that only contained data relating to other psychometric properties were 
excluded, e.g. reliability, face validity, and content validity. 
 
Data extraction and synthesis: Data were extracted by one reviewer using a newly developed form, 
designed for specific use in the review. Due to heterogeneity between studies, a narrative synthesis 
was performed and data tabulated according to the psychometric quality assessed, namely construct 
validity and responsiveness. Papaioannou et al. used definitions of validity and responsiveness as 
follows: construct validity, the degree to which an instrument measures the construct it is designed 
to measure and in the settings it is designed to measure. This can be measured by one of two 
methods. Known or extreme groups: where two groups who differ in a trait or behaviour, one group 
is expected to score significantly higher or lower on a particular measure compared with the other 
group (definition from Streiner 2003); Convergent validity: where the relationship between two 
ŝŶƐƚƌƵŵĞŶƚƐŵĞĂƐƵƌŝŶŐƚŚĞƐĂŵĞĐŽŶƐƚƌƵĐƚŝƐĂƐƐĞƐƐĞĚďǇWĞĂƌƐŽŶ ?ƐƉƌŽĚƵĐƚŵŽǀĞŵĞŶƚĐŽƌƌĞůĂƚŝŽŶ
or SpearmaŶ ?Ɛ ƌĂŶŬ ĐŽƌƌĞůĂƚŝŽŶ ?(7)  The review used the following categories for evidence of 
ĐŽƌƌĞůĂƚŝŽŶ P AN ? ? ? ǀĞƌǇ ƐƚƌŽŶŐ ? A? ? ? ? ƚŽ AN ? ? ? ƐƚƌŽŶŐ ? A? ? ? ? Ž A?  ?  ŵŽĚĞƌĂƚĞ ? A? ? ? ? ǁĞĂŬ ? ^ĞĐŽŶĚůǇ ?
responsiveness was defined as the extent to which an instrument can detect a clinically significant or 
practically important change over time (definition from Walters 2009).(8) 
 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ 
The authors concluded that the current available evidence for use of the EQ-5D in patients with 
schizophrenia was mixed, and that there was not enough evidence to recommend the use of EQ-5D 
in this population to National Institute for Health and Care Excellence (NICE) or other such agencies.   
 
4.1.3 Assessment of the review in relation to objectives of work package 1.1 
Relevance of review question: The aim of Papaioannou et al 2011 was concordant with the aims of 
WP1.1.  
 
Assessment of review quality: Assessment of the quality of the review was conducted using a 
modified version of the Assessing the methodological quality of systematic reviews (AMSTAR) tool 
and also by considering the strength and quantity of the evidence.(9) The adequacy of the reported 
data in the context of WP1.1 was also assessed.  A summary of the quality assessment is shown in 
the Appendix. 
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Pappaioannou et al. (2011) scored well against most of the relevant AMSTAR criteria. 
Inclusion/exclusion criteria were clearly defined. Quality assessment of the included studies was 
conducted and whilst no formal method for assessing the quality of this type of study has been 
previously validated, methods published elsewhere were followed.(10)  However, there was no 
reference to a published protocol to evidence an a priori design, therefore increasing the risk of 
reporting bias in terms of changes to the analysis plan in response to the results found. Study 
selection was carried out by only one reviewer, and double data extraction or data-checking was not 
conducted, leaving the study at higher risk of errors.  
 
Acceptability of the search: Comprehensive search strategies have been fully reported in the review. 
A clear description of the iterative approach to the search was applied. Four different iterations 
were applied: keyword searching; broader terms combined with quality of life (QoL) terms 
searching; and Quasi QoL terms. The search is considered comprehensive.  
 
Acceptability of study selection: Study selection criteria were clearly defined and concordant with 
the inclusion criteria for WP1.1 
 
Adequacy of available data and synthesis:  The review only provided a small amount of data relating 
to each study, however this was adequate for the requirements of WP1.1. 
 
In conclusion, the methods employed in the review were generally of an acceptable quality and 
design to meet the requirements of WP1.1. However, the review concluded that there was not 
enough evidence to recommend the EQ-5D for use by NICE or other such agencies in this patient 
population. The searches for the review were conducted in August 2009. As such, an update of this 
review was conducted, to identify any additional evidence relating to the assessment of the EQ-5D in 
schizophrenia, and a narrative synthesis combining the studies from Papaioannou et al 2011 (4) with 
newly identified studies is provided below.  
 
4.1.4 Results of the update and reanalysis of Papaioannou et al 2011(4)  
A total of 33 studies were included in Papaioannou et al 2011.(4) Eight of these studies evaluated 
the construct validity or responsiveness of the EQ-5D. The remaining studies focused on the other 
generic measures (SF-36, SF-12, SF-6D) and therefore did not meet the inclusion criteria of WP 1.1 
and were not included in this synthesis.  
 
13 
 
Update searches were conducted by EEPRU in May 2014 and retrieved 87 unique titles (search terms 
given in Appendix B). Of these, the full text of 37 were obtained and considered for inclusion in the 
review. Two studies met the inclusion criteria and were not already included in Papaioannou et 
al.(3;6)  A total of 10 studies are therefore included in this review.  
 
Of the ten included studies, two studies used the UK EQ-5D tariff.(1;2) Pitkanen et al. used Finnish 
weights.(3)  No further details of which EQ-5D tariff was used for the remaining 7 studies are 
provided in Papaioannou et al.(4) Only two studies were conducted in the UK.(4-6) The remaining 
studies were conducted in other European countries, two in Germany,(1;11) two in the 
Netherlands,(12;13) one in Spain,(14) one in Italy,(15) one in Finland(3) and one not reported.(16) 
 
Patient characteristics were fairly similar across studies. Mean ages ranged from 28.9 years(4) to 
41.5 years.(12) Four studies included only patients with schizophrenia, as classified by the ICD-
10,(14) Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview,(12) or unreported 
method of classification.(13;16) Three studies included patients with schizophrenia, schizotypal or 
delusional disorders as classified by the ICD-10(1;3;11), and one included patients with schizophrenia 
or schizophreniform disorder.(15) One study included patients with a diagnosis of non-affective 
psychosis, which included schizophrenia, schizoaffective disorder, bipolar disorder, and psychotic 
depression),(4) whilst another included young adults (aged 14 to 35) with first-episode psychosis.(6) 
This diagnosis included schizophrenia, schizophreniform disorder, schizo-affective disorder, biopolar 
disorders type 1 and 2, delusional disorder and major depressive disorder. The number of 
withdrawals and study designs were not reported consistently by Papaioannou et al.(17) 
 
A range of measures were used to assess the construct validity and/or responsiveness of the EQ-5D. 
The majority of measures used were designed for use in mental health conditions, or to capture 
mental health symptoms: Positive and Negative Syndrome Scale (PANSS), Beck anxiety inventory 
(BAI), Beck depression inventory (BDI), or Beck Hopelessness Scale (BHS);(4;5;13;15)  symptom 
checklist 90 (SCL-90-R) or clinical global impression-severity (CGI-S);(1;11;14;15) Bech WRafaelsen 
melancholia scale (BRAMES);(1) brief psychiatry rating scale (BPRS);(12) Auditory hallucinations 
rating scale (AHRS).(13) Most also included a measure of functioning: Global Assessment of 
Functioning Scale (GAF), Social and Occupational Functioning (SOFAS), global assessment of 
relational functioning scale (GARF), Health of the nation outcome scales (HoNOS);(1;3-5;11;14) or 
Groningen social disabilities schedule (GSDS).(13) A few studies compared the EQ-5D with another 
generic quality of life measure: WHO quality of life BREF (WHOQOL-BREF),(1;11;13) Quality of Life 
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Scale (QLS);(5) or a disease specific quality of life measure: Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q).(3) One study did not conduct a comparison, and instead performed a 
Rasch analysis.(6)  
 
Acceptability: The review did not report any data for acceptability, and neither did either study 
identified in the update search.  
 
Construct validity (known group): Two studies reported data on construct validity using the known-
groups method.(3;5) Using a minimally important clinical difference (MID) of >0.03, Barton et al. 
found a significant difference in mean EQ-5D index scores between those with milder and those with 
more severe symptoms and functioning.(5) Pitkanen et al. dichotomised patients using a cut-off of 
 ? ?A?'&Žƌ'&AN ? ? ?ĂŶĚĨŽƵŶĚĂƐƚĂƚŝƐƚŝĐĂůůǇƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞ ?ƉA? ? ? ? ? ?ŝŶďŽƚŚĐĂƐĞƐ ?ďetween 
the means of the two groups for both the EQ-5D and the Q-LES-Q (which measures enjoyment and 
satisfaction). When comparing across diagnosis sub-groups (ICD-10: F20 vs. F21-F29) no significant 
difference was reported for either the EQ-5D (p=0.350) or the Q-LES-Q (p=0.354).(3) Pitkanen et al. 
also reported that both the EQ-5D and the Q-LES-Q, met the criteria for principle component 
analysis with all dimensions on both measures scoring over 0.5 (0.4 used as cut-off) and all except 
mobility in the EQ-5D dimensions scoring above 0.65.(3) 
 
Construct validity (convergent):  Seven studies(1;3;5;11;12;14;15) tested the convergent validity of 
the EQ-5D compared to a variety of other measures such as the PANSS, GAF, Hamilton depression 
ratings scale, QLS, SOFAS, CGI-S, or BPRS (Appendix).  The statistical significance (p-values) were 
generally not reported in Papaioannou et al. Correlations between the EQ-5D and  symptom and 
functional measures showed differences between studies in the strength of these relationships, 
ranging from non-existent to strong.  Barton explored the relationship between the EQ-5D and three 
symptoms measures (BAI, BDI, BHS), with resulting correlations ranging from moderate to very 
strong (r: 0.360 to 0.656). They also found a weak but significant relationship with a measure of 
functioning (GAF, r=0.263). However correlations with the PANSS, were not significant.(5)  Scalone 
2008 also reported the relationship between the EQ-5D and the symptom measure PANSS, was non-
existent or mostly weak.(15)  Prieto 2004 showed moderate to strong correlations with both 
symptom and functional measures (CGI-S and GAF),(14) and McCrone found a moderate correlation 
(r=0.343 p not reported) with the BPRS at baseline.(12) Konig 2007 examined effect sizes for the 
mean values of symptom and functioning measures between individuals who answered either yes 
(extreme problems and moderate problemƐ ǁĞƌĞ ĐŽůůĂƉƐĞĚ ŝŶƚŽ Ă  ?ǇĞƐ ? ĐĂƚĞŐŽƌǇ ďǇ <ŽŶŝŐ ĚƵĞ ƚŽ
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small numbers of extreme problems) or no problems on each of the dimensions of the EQ-5D. Effect 
sizes were moderate to large ranging from 0.37 to 1.29 for symptom measures, and from 0.24 to 1.4 
for functioning measures, although the effect sizes for EQ-5D pain/discomfort responses were 
smaller (data not reported).(11) 
 
For other quality of life measures, Konig 2007 found moderate to strong correlations between EQ-5D 
and the HoNOS, but weak to moderate correlations with the GARF.(11)  Barton 2009 found a weak, 
non-significant relationship between EQ-5D and both the QLS and SOFAS,(5) and Pitkanen et al. 
found weak to moderate correlations to the Q-LES-Q items, with correlations ranging from 0.28 to 
0.47 (all except mobility greater than 0.30), and a moderate overall correlation between the two 
measures (r=0.455, p<0.001).(3) 
  
Responsiveness (changes over time): Four studies assessed responsiveness by examining changes 
over time (Appendix).  Results for responsiveness were again mixed. Positive result were found by 
Barton 2009 and Badia 1999, with Badia showing large effect sizes (1.13) for olazapine treated 
patients, and moderate to large effect sizes for patients treated with other antipsychotics (0.78 to 
0.96) (NB, assuming olazapine is more effect than the others with no adverse effect on HRQoL).(16) 
A significant difference in improvement in mean EQ-5D scores between improvers and non-
improvers was found by Barton 2009, where improvement was classified as MID (0.03).(5) However, 
van de Willige (2005) found a lack of responsiveness to change for most of the symptom and 
functioning measures.(13) Correlations between change scores on the EQ-5D and other clinical 
measures showed few significant correlations, one for a PANSS subscale (positive), r= 0.53, p<0.001), 
and one for a subscale of AHRS (distress, r= 0.25, p<0.01). Analyses of the relationships between EQ-
5D and social function (GSDS) showed a range of correlations (from 0.29 to 0.39, p ranges p<0.005 to 
p<0.05). For generic health measures, correlations between EQ-5D and WHOQoL-Bref ranged from 
0.25 to 0.58.(13) 
 
Rasch analysis: One study assessed the psychometric properties of the EQ-5D using Rasch analysis in 
young adults with first episode of psychosis (mean PANSS score =62.7).(6) The authors concluded 
that the EQ-5D is valid in this population but there was a possible bias for the health dimensions 
anxiety/depression and usual activities across ethnic groups (white vs. non-white), and was 
potentially more suitable for comparing mean values across groups of patients (e.g. major 
depressive disorder vs. schizophrenia), or over time, than for individuals. 
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4.1.5  Conclusion of appropriateness of EQ-5D in schizophrenia 
The evidence base assessing the psychometric properties of the EQ-5D in patients with 
schizophrenia was relatively large (n-10) and at least nine of these used the UK EQ-5D index.  
However, not all psychometric properties were reported and overall the results were mixed.  The 
construct evidence (known groups) was good with two studies reporting that the EQ-5D detected 
differences in the expected direction for known groups, characterised by function (GAF), severity 
(PANNS) and condition (ICD).(3;5) However, the evidence for both responsiveness and convergent 
validity was mixed.  For responsiveness, while there was some evidence that the EQ-5D was 
responsive to change, this evidence was limited to the PANSS positive subscale, the Groningen social 
disabilities schedule (GSDS) and the auditory hallucinations rating scale (AHRS), and no association 
was found when changes in the BPRS were small (<25%). Finally, despite one study reporting 
moderate to large effect sizes (ES) for both symptom and function measures, the relationship 
between the EQ-5D and symptoms (function) was reported as poor in three (three) studies.     
 
In conclusion, there is sufficient evidence to raise doubts about the appropriateness of the EQ-5D in 
patients with schizophrenia (Table 1). 
 
Table 1: Summary of evidence on EQ-5D for schizophrenia 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (11) Not reported         Not 
reported            
      Good; Mixed Mixed; Not 
reported 
 
                   Sufficient evidence to raise doubts about the appropriateness of EQ-5D in schizophrenia        
 
 
 
4.2 Alternative measures in schizophrenia (WP1.2) 
The evidence relating to the appropriateness of the EQ-5D in schizophrenia raised sufficient doubts 
to warrant consideration of other measures in schizophrenia.  
 
Searches identified three reports of relevance to WP1.2 (Appendix)(18-20) and one set of 
presentation slides from the Royal College of Psychiatrists, which describes the National Audit of 
Schizophrenia (NAS). The latter is considered in detail in WP1.3, and will not be described here.  
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Whilst none of the three reports described their methods clearly (at least two were the product of 
expert panels/working groups, but the process is not described), and none necessarily considered 
psychometric properties, all three recommend the same measures, namely the BPRS and the 
positive and negative syndrome scale (PNASS). The EMA report states that these are reliable and 
validated measures, but does not provide evidence to support this statement.(20) Both measures 
are clinician-completed, which may be a necessity in this patient group. However, the National Audit 
of Schizophrenia takes a wider view of outcomes, and includes questions to be completed by the 
clinician, the patient and carers.  
 
In addition to the literature found through searches, it is worth noting that in the recent introduction 
of Payment by Results in the area of mental health, providers are mandated to collect a Patient 
Reported Experience Measure (PREM), Clinician Reported Outcome Measure (CROM) and a 
PROM.(21) The recommended CROM and PREM are HoNOS and Friends and Family Test respectively 
(DH 2013). In terms of the PROM, the Warwick Edinburgh Mental Well Being Scale (WEMWBS) or 
the short version (s-WEMWBS) is currently recommended and both are being tested by the Care 
Pathways and Packages Project.(22)  The WEMWBS was developed for use in the general population 
and is currently being validated in the area of mental health.  
 
In the meantime, there is recognition that a new measure is needed that would be suitable across 
the wide spectrum of psychotic and non-psychotic mental health conditions.(23) As already 
described in section 9.2, the Recovering Quality of Life (ReQoL) instrument, a new preference-based 
measure in the area of mental health, is being developed by the Policy Research Unit in Economic 
Evaluation of Health and Care Interventions and is due to be available around July 2015.  The ReQoL 
will have both a long and a short version and will be suitable for use across the psychotic (which will 
include anxiety and depression) and non-psychotic (which will include schizophrenia) conditions.  
Once the measure is available and has been validated in people with schizophrenia, the ReQoL may 
become a candidate measure for inclusion in the NCA.    
 
 
 
4.3 Evidence for economic evaluations in schizophrenia (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in schizophrenia 
Just one single technology appraisal (STA) relating to schizophrenia was identified from the 
searches.(24) The evaluation compared pharmacological treatments for schizophrenia in adolescents 
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(15-17 years).   A Markov model with discrete health states based on maintenance and relapse (plus 
death) was used after an initial decision tree for treatment switching was used to compare the cost-
effectiveness of three lines of treatment (Table 2, Figure 1).  As treatment related adverse events 
such as substantial weight gain and somnolence are prevalent, and frequently lead to 
discontinuation of treatment, these were also captured within the model framework.  
 
Clinical trial data were used to inform the treatment specific probabilities of weight gain (>7%), 
somnolence and discontinuation due to: lack of efficacy, adverse events or other reasons.  The long-
term risk of relapse was modelled using relative risks obtained from the literature.   Evidence from 
adults was used due to lack of more suitable data in adolescents. 
 
Quality adjusted life years (QALYs) were obtained by assigning mean utility values to the discrete 
health states.  Again, due to lack of more suitable data in adolescents, EQ-5D data collected from 
adults were used.  The results of the searches conducted to inform the model parameters suggest 
the volume of EQ-5D data in patients with schizophrenia is very limited and none were available in 
adolescents.  
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Figure 1: Modelling approach used in the schizophrenia HTA 
 
 
Legend: Orange framed boxes with uppercase text describe the health states used in the schizophrenia TA 
model while the purple framed boxes with lower case (plain) text describe the evidence used.  Italised text 
indicative of additional variables which would be informative for future economic evaluations in psychological 
therapies. 
 
 
 
Table 2: Summary of existing models used in schizophrenia HTAs 
 Model method, clinical effect  Method used to model utilities  
STA (TA213): Schizophrenia  W aripiprazole (in adolescents); 2011(24) 
 Decision tree followed by Markov model  
Discrete health states: maintenance, relapse, 
death 
Effectiveness: probabilities (weight gain, 
somnolence, discontinuation)  
Source: RCTs used for clinical effect 
Utility: EQ-5D; mean values assigned to discrete HS 
Source: published literature 
AEs: disutilities due to weight gain (>7%) and 
somnolence included 
HS: health states; AE: Adverse Events; STA: Single Technology Appraisal; RCT: randomised controlled trial 
 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for patients with schizophrenia: 
 
x Pharmaceutical intervention(s) 
x Compliance to intervention 
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x Treatment related adverse events (such as weight gain, somnolence) 
x Discontinuation rates (and reason) 
x Recurrence/relapse rates (with dates) 
x Utility values 
 
The majority of this evidence would need to be dated and linked through timings of collection.   
 
4.3.2 Fields collected in the schizophrenia NCA  
The NCA for schizophrenia comprises of data collected from eligible Trusts and Health Boards in 
England and Wales, and collects information on patients diagnosed with schizophrenia (ICD10: 
F20.0-F20.9) or schizoaffective disorder (ICD-10: F25.0-F25.9) who are treated in the community, 
including nursing homes and residential care but not inpatients.  The fields in the schizophrenia NCA 
are collected via three questionnaires; an audit tool completed by the psychiatrist accountable for 
ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ĐĂƌĞ ?(25) Ă ƐĞƌǀŝĐĞ ƵƐĞƌ ?Ɛ ƋƵĞƐƚŝŽŶŶĂŝƌĞ ? ĂŶĚ Ă ĐĂƌĞƌ ?Ɛ ƋƵĞƐƚŝŽŶŶĂŝƌĞ ?  WĂƚŝĞŶƚƐ ĂƌĞ
randomly selected from within the Trust/Health Board from patients who meet the criteria for the 
National audit of schizophrenia (NAS).  The fields are provided in the Appendix.   
 
The mandatory fields provide information on patient characteristics (age, gender, ethnicity); current 
health status (full remission, partial remission with minimal symptoms, partial remission with 
substantial symptoms, not in remission) current antipsychotic medications, comorbidity (history of 
cardiovascular disease, diabetes, hypertension or dyslipideamia), and psychological therapies 
(cognitive behavioural therapy, family therapy).  The optional fields provide additional information 
on current and historical use of antipsychotic medications for patients not currently in remission; 
physical health status (smoker, alcohol intake, current measures of: body mass index, blood 
pressure, lipids, glucose) and interventions offered for these; and whether psychological therapies 
were taken up by the patient if offered (Appendix). 
 
The service-user and carer questionnaires provide information on experience of, and satisfaction 
with, the health services provided (Appendix).  There are no HRqoL data currently collected in the 
audit.  Both questionnaires are completed anonymously hence cannot be matched to patient 
records. 
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4.3.3 Comparing fields in schizophrenia NCA with variables used in existing HTAs  
The mandatory fields in the schizophrenia NCA do not provide sufficient detail to model the 
individual treatment effects (maintenance, relapse, weight gain etc) as applied in the existing HTA 
cost-effectiveness evaluations in schizophrenia.  Although remission (full or partial) is a mandatory 
field, it is believed these records are subjective clinical decisions.  If this is the case, this evidence 
could be improved through the use of a clinical instrument with clearly defined criteria for remission.  
The rate of patients in remission could then be used to inform economic models comparing 
interventions or providers.  Some of the optional fields in the clinical audit tool, such as the use of 
antipsychotic medications and history of medications in patients not in remission, could supply some 
of the additional evidence required to model the cost-effectiveness of different interventions and 
policies.    
 
Both the service user and carer questionnaires are principally formed around qualitative questions 
relating to experiences of the health care services and information provided by the clinicians.  
Although this is valuable information, it would not be incorporated within an economic modelling 
which requires information on costs and clinical benefits (i.e. QALYs).  There are currently no data 
collected in the schizophrenia NCA which could be used to inform the HRQoL associated with the 
condition or the interventions prescribed.  As far as we are aware, there are no scheduled plans for 
imminent inclusion of any generic or condition specific PROM.  A mechanism to link the service-user 
and patient responses to the clinical audits, together with the inclusion of a variable which could be 
used to generate preference-based utilities would greatly enhance the dataset.   
 
 
 
4.4 Recommendations for schizophrenia 
Based on the evidence reviewed, the EQ-5D is not thought to be appropriate for patients with 
schizophrenia.  It is not believed that there are data in the schizophrenia NCA which could be used to 
inform the HRQoL associated with the condition, either directly through a preference-based 
measure, or indirectly through an alternative measure.  In addition, it is not believed that the other 
variables collected in the audit will suffice to compare providers or conduct robust economic 
evaluations.  Potential recommendations (PR) and areas for future research (FR) are discussed 
below.  All suggested future research areas are indicative and would require a discussion and 
detailed proposal if required. 
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It is recommended that both the HoNOS (a clinician-completed measure) and the WEMWBS are 
collected in the NCA (PR.1).  As the WEMWBS is not a preference-based measure, it cannot be used 
to generate QALYs in economic evaluations.  It is therefore recommended that the ReQOL is 
collected in future rounds of the audit once it has been validated in schizophrenia.(PR.2)  It is also 
recommended that the psychometric properties of the ReQOL is assessed in detail using the data 
collected in the schizophrenia NCA (FR.1). 
 
The schizophrenia audit does not currently collect suffient detailed information to compare 
providers or perform economic evaluations.  Additional mandatory fields to capture the information 
required would increase the felexibility of the secondary use of the data (PR.3).  Formal 
recommendations of which fields to include would require a detailed inspection of the exact data 
collected in the current schizophrenia audit (FR.2). 
 
 
Table 3: Recommendations and associated future research for schizophrenia 
PR.1 Include both the HoNOS (a clinician-completed measure) and WEMWBS in the 
schizophrenia NCA 
PR.2 Include the ReQOL in the NCA once available and validated in patients with schizophrenia 
FR.1 Assess the psychometric properties of the ReQOL using the data collected in the NCA 
PR.3 Increase the mandatory fields in the NCA to facilitate future economic evaluations 
FR.2 Inspect the fields collected in the NCA with a view to making recommendations on the 
information required to compare providers and conduct economic evaluations 
  
23 
 
5.  SUMMARY   
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
An existing review was updated. A total of ten primary research studies were identified. Evidence 
was mixed (Table 4). Construct validity by known group (defined by severity, diagnosis subgroup and 
function) was good, but both construct validity by convergent methods and responsiveness by 
change over time were mixed. The EQ-5D was responsive to change over time in two studies, but the 
correlations between change scores in another study were only significant between the EQ-5D and 
an affect subscale (PANSS positive subscale), a social function scale (GSDS) and an auditory 
hallucination scale (AHRS). Small changes were not reflected in the EQ-5D scores. There are 
sufficient concerns with the EQ-5D in this population to prevent its recommendation. Three 
guidelines relating to other measures were identified and all recommended using the BPRS and the 
PANSS. Within the recently introduced payment by results initiative, the patient-reported measures 
used are WEMWBS and s-WEMWBS, and a clinician-reported measure, HoNOS, is also used. It is 
recommended that the same measures are used for the NCA. In this population, it may be useful to 
include a clinician-reported measure alongside patient-reported measures. ReQoL, could be 
considered as an alternative once available. 
 
Table 4: Summary of evidence currently available for recommended measure(s) 
Condition N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D 10 NR NR Good Mixed Mixed NR Not 
appropriate 
HoNOS 
(clinician-
completed) 
 The recommendation is based on those in PBR [DH2013] and the psychometric 
properties of this measure have not been reviewed in the current report  
WEMWBS  The recommendation is based on those in PBR [DH2013] and the psychometric 
properties of this measure are currently under review elsewhere [DH3013] 
ReQOL  This measure is currently in development and will be available in 2015 
         
N= number of studies used to inform conclusions, KGV: known group validity; NR, the existing review did not 
review this psychometric property. 
 
5.2 Summary of evidencerequired for use in economic evaluations (WP1.3) 
Although the audit includes a service user and carer questionnaire, these do not currently include a 
PROM, concentrating of experience of and satisfaction with the health services provided.  These 
data will be useful when comparing providers, but cannot be used to inform economic evaluations.  
It is not believed that the mandatory fields in this audit provide sufficient detail to model individual 
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treatment effects (maintenance, relapse, compliance, weight gain etc), but some of the optional 
fields could provide some evidence on antipsychotic medications and history of medications in 
patients not in remission ?tŚŝůĞƚŚĞƌĞŝƐĂŵĂŶĚĂƚŽƌǇĨŝĞůĚƌĞůĂƚŝŶŐƚŽ ?ƌĞůĂƉƐĞ ?ŝƚŝƐďĞůŝĞǀĞĚƚŚŝƐŝƐĂ
subjective clinical decision, thus it may not be possible to use this in economic models. 
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APPENDIX: SCHIZOPHRENIA 
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for 
Schizophrenia.  
 
Table A1: Quality assessment of Papaioannou et al 2011 systematic review of schizophrenia.(4) 
Quality assessment criteria Compliance with criteria 
AMSTAR  
Was an a priori design provided? Yes 
Was there duplicate study selection and data 
extraction? 
No 
Were the methods used to combine the findings of 
the studies appropriate? 
Yes, narrative synthesis due to heterogeneity 
Was the scientific quality of the included studies 
assessed and documented? 
Yes, using method described in Fitzsimmons et al.(26) 
Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
Yes 
Overall judgement of quality of review Good but only 1 reviewer 
Quality of the searches  Acceptable 
Strength of the evidence  
Were the conclusions robust and conclusive? No, evidence was mixed and limited 
Quantity of the evidence  
Was there enough data to be confident that any 
additional data published subsequently would be very 
unlikely to change the conclusions drawn? 
No because evidence was mixed 
Adequacy of data reported  
Did the review provide sufficient data to allow 
integration of an update/assessment of the methods 
used? 
Yes 
Did the review assess EQ-5D in a way compatible with 
the aims of work package 1.1? 
Yes, construct validity (known groups or convergent) 
or responsiveness (effect sizes, standardised response 
means, or correlation with change scores on 
symptom measures). 
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Table A2: Characteristics of primary studies for Schizophrenia. Partly adapted from Pappaionnou et al 2011.(4) 
Author, year Study design Condition Study information Male/female Mean (SD) age at 
baseline in years 
Badia, 1999, country not 
reported(16) 
N/R Schizophrenia (classification N/R) N=approx 2949 
n=2128 olanzapine 
n=821 risperiodone or 
haloperidol; small numbers on 
other antipsychotics 
N/R N/R 
Barton, 2009, UK(5) N/R Current diagnosis of affective or 
non affective psychosis including 
schizophrenia, schizoaffective 
disorder, bipolar and psychotic 
depression in relative remission 
 ?WE^^A? ? ? 
N=77 55/22 28.9  
range 18-52 
Konig, 2007, Germany(1) N/R ICD-10: schizophrenia, schizotypal 
or delusional disorders 
N=166 97/67 40.5 (11.1)  
range 21-80 
Konig, 2009, Germany(27) N/R ICD-10: schizophrenia, schizotypal 
or delusional disorders 
N=143 83/60 40.4 (11.6) 
McCrone, 2009, 
Netherlands(12) 
N/R SCAN interview diagnosed 
schizophrenia (classification 
scheme not specified) 
N=409 245/164 41.5 (11.5) 
Prieto, 2004, Spain(14) N/R ICD-10 schizophrenia N=2657 
n=2128 olanzapine, n=417 
risperidone, n=112 haloperidol  
1691/966 35.32 (11.57) 
Scalone, 2008, Italy(15) N/R Schizophrenia, schizophreniform 
disorder 
N=637 
n=551 schizophrenia, n=86 
schizopherniform disorder 
414/223 N/R,  
range 18-40  
Van de Willige, 2005, 
Netherlands(13) 
N/R DSM-IV schizophrenia (chronic 
sample). Auditory hallucinations > 2 
years, use of at least 2 antipsychotic 
drugs 
N=76 42/34 36 (11.2) 
Studies from update search 
Pitkänen, 2011, 
Finland(3) 
Cross-sectional Hospitalised patients with diagnosis 
of schizophrenia, schizotypal 
disorders 
N=311 
41% schizophrenia 
29% non-organic psychotic 
183/128 38 (13) 
Range 18-65 
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Author, year Study design Condition Study information Male/female Mean (SD) age at 
baseline in years 
or delusional disorders (ICD10: 
F20 W29) 
disorder 
16% schizoaffective disorder 
6% acute and transient psychotic 
disorder 
5% persistent delusional disorder 
2% schizotypal disorder 
1% other non-organic psychcotic 
disorder 
Stochl, 2013, UK(6) Cross-sectional Young adults (aged 14 to 35) with 
first-episode psychosis 
N=1,027 recruited, 714 with 
complete data and known 
diagnosis. 
22% Schizophrenia 
4% Schizophreniform disorder 
6% schizo-affective disorder 
2% bipolar disorder 1 
4% Bipolar disorder 2 
4% delusional disorder 
7% major depressive disorder 
29% psychosis, not otherwise 
specified 
21% diagnosis not available 
709/318 Median 22 (IQR 19 to 26) 
Range 14 to 35 
PANSS: Positive and Negative Syndrome scale 
,  
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Table A3: Characteristics of primary studies for schizophrenia. Partly adapted from Pappaionnou et al 2011. (4) 
Author, Year, 
Location 
EQ-5D Comparison measure Psychometric 
properties assessed 
Assessment of psychometric properties 
Badia, 1999, country 
not reported(16) 
EQ-5D Index and 
EQ-5D VAS 
No measures reported Responsiveness Effect sizes for EQ-VAS and EQ-5D index (no further details) 
Barton, 2009, UK(5) EQ-5D Index Patient completed: 
i)Severity of mental health 
symptoms: BAI, BDI, BHS, GAF 
Clinician-completed: 
i)Severity of mental health 
symptoms: PANNS 
ii)Functioning: QLS, SOFAS 
Construct validity  W 
known-groups 
 
Differences in EQ-5D scores (% reporting problems on EQ-5D 
health dimensions) when sub-ŐƌŽƵƉĞĚďǇƐĞǀĞƌŝƚǇ P/ ?A? ? ?ǀƐ ?
A? ? ? ? ?/ ?A? ? ?ǀƐ ?A? ? ? ? ?,^ ?A? ?ǀƐ ?A? ? ? ?'& ?A? ? ?ǀƐ ?
^K&^ ?A? ? ?ǀƐ ?A? ? ? ? ? 
for all above and for PANNS and QLS also compared sub-groups 
of equal size (when ranked by severity) 
Convergent validity Correlation between EQ-5D and all other measures  
Responsiveness Mean EQ-5D scores for sub-groups who improved (post 
intervention) assessed by clinical measures (BAI, BDI, NHS, QLS, 
PANSS, GAF, SOFAS) 
Konig, 2007, 
Germany(11) 
EQ-5D Index and 
EQ-5D VAS 
Clinician-completed: 
i)Symptoms PANSS, SCL-90R & 
CGI-S 
ii)Functional GAF, GARF, SOFAS 
& HoNOS 
Patient-completed: 
i)Quality of life-generic TTO 
direct utility & WHOQOL-BREF 
Convergent validity Effect sizes calculated using the mean values of symptom and 
ĨƵŶĐƚŝŽŶŝŶŐŵĞĂƐƵƌĞƐďĞƚǁĞĞŶŝŶĚŝǀŝĚƵĂůƐǁŚŽĂŶƐǁĞƌĞĚ ?ǇĞƐ ?
Žƌ ?ŶŽ ?ĨŽƌĞĂĐŚY-5D dimension 
 
Correlations between EQ-5D VAS and index and 
symptom/functioning measures 
Konig, 2009, 
Germany(1) 
EQ-5D Index (UK 
and German) 
Clinician-completed: 
i)Symptoms PANSS, SCL-90R, 
CGI-S, and BRAMES 
ii)Functional GAF, GARF, SOFAS, 
and HoNOS 
Patient-completed: 
i)Quality of life-generic TTO 
direct utility & WHO-QOL-BREF 
Convergent validity Correlations between EQ-5D and symptom and functional 
measures 
McCrone, 2009, 
Netherlands(12) 
EQ-5D Index Clinician-completed: 
i)Symptoms BPRS 
Convergent validity Correlations between EQ-5D Index and symptom measure at 
baseline and change after treatment 
Responsiveness SRM 
Prieto, 2004, 
Spain(14) 
EQ-5D Index  Clinician-completed: 
i)Symptom CGI-S 
Convergent validity Correlations between EQ-5D and symptom and functional 
measures 
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Author, Year, 
Location 
EQ-5D Comparison measure Psychometric 
properties assessed 
Assessment of psychometric properties 
ii)Functional GAF 
Scalone, 2008, 
Italy(15) 
EQ-5D Clinician-completed: 
i)Symptom PANSS, CGI-S 
ii)Functional GAF 
Convergent validity Correlations between EQ-5D and symptom and functional 
measures 
Van de Willige, 2005, 
Netherlands(13) 
EQ-5D Index  Clinician-completed: 
i)Symptom PANSS, AHRS 
ii)Functional GSDS 
iii)Quality of life-generic 
WHOQOL-BREF 
Responsiveness Differences in EQ-5D descriptive system scores between 
baseline and follow-up. Correlations between changes in EQ-5D 
and symptom and functional measures 
Studies from update search 
Pitkänen, 2012, 
Finland(3) 
EQ-5D (Finnish 
weights) 
Q-LES-Q (general activities) 
Nurse completed: GAF 
Internal consistency Correlation between EQ-5D health dimensions and 14 items on 
Q-LES-Q 
Sub-groups defined by GAF scores 
^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶŽĨŽǀĞƌĂůůƐĐŽƌĞƐ ? 
Construct validity Principle component analysis 
Mann Whitney used to test for differences in EQ-5D index and 
Q-LES-Q  total sub-ŐƌŽƵƉďǇ'&A䜃? ?ǀƐ ?'&>50, and diagnosis 
group (Dg) F20 vs F21-29 
Stochl, 2013(6) EQ-5D (UK) Diagnostic subtypes Rasch analysis Item response modelling 
Relationship between EQ-5D and diagnosis 
Differential item functioning 
BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; BHS: Beck Hopelessness Scale; PANSS: Positive and Negative Syndrome Scale; GAF: Global Assessment of 
Functioning Scale; QLS: Quality of Life Scale; SOFAS: Social and Occupational Functioning; S-QOL, schizophrenia quality of life scale;  Q-LES-Q: Quality of Life Enjoyment and 
Satisfaction Questionnaire; Db, diagnosis group; BRAMES, Bech-Rafaelsen Melancholia Scale;  
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Table A4: Convergent validity results for schizophrenia, adapted from Pappaionnou et al 2011 (4) 
Author, year Method of measuring convergence (e.g. Spearman rank 
correlation, statistical significance) 
Convergent validity results 
 ?EĂŶǇƐƵďũĞĐƚŝǀĞĚĞĐŝƐŝŽŶƐŽĨ ?ƐƚƌĞŶŐƚŚ ?ĂƌĞĂƐƌĞƉŽƌƚĞĚŝŶWĂƉƉĂŝŽŶŶŽƵ ? 
McCrone, 2009(12) Correlations between EQ-5D Index and symptom 
measures: 
 
Clinician-completed: 
i) Symptoms BPRS 
EQ-5D and BPRS: r=0.343 (moderate) 
Konig, 2007(11) Effect sizes calculated using the mean values of symptom 
and functioning measures between individuals who 
ĂŶƐǁĞƌĞĚ ?ǇĞƐ ?Žƌ ?ŶŽ ?ĨŽƌĞĂĐŚY-5D dimension * 
 
Correlations between EQ-5D VAS and index and 
symptom/functioning measures: 
 
Clinician-completed: 
i)Symptoms PANSS, SCL-90R & CGI-S 
ii)Functional GAF, GARF, SOFAS & HoNOS 
Patient-completed: 
i)Quality of life-generic TTO direct utility & WHOQOL-BREF 
Effect sizes mostly moderate to large for symptom measures (0.37-1.29) 
and functioning measures (0.24-1.4) 
Effect sizes for pain/discomfort were smaller 
Moderate correlations between EQ-5D VAS and index and symptom 
measures (0.34-0.73), functioning measures (0.20-0.65), and generic QoL 
measures (0.47-0.57) 
Konig, 2009(1) Correlations between EQ-5D and symptom and functional 
measures: 
 
Clinician-completed: 
i)Symptoms PANSS, SCL-90R, CGI-S, and BRAMES 
ii)Functional GAF, GARF, SOFAS, and HoNOS 
Patient-completed: 
i)Quality of life-generic TTO direct utility & WHO-QOL-
BREF 
Correlation with the TTO direct elicitation of utility values and the EQ-5D 
VAS and EQ-5D index (UK and German) were weak in correlation (0.25). 
However, the TTO method did not correlate well with a number of 
theoretically related measures. 
 
 
Prieto, 2004(14) Correlations between EQ-5D and symptom and functional 
measures: 
 
Clinician-completed: 
i)Symptom CGI-S 
Moderate to strong correlation with one symptom (CGI-S) and one 
functional measure (GAF) (range 0.34-0.54, p<0.001) 
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ii)Functional GAF 
Barton, 2009(5) Correlations between EQ-5D and symptom measures: 
 
Patient completed: 
i)Severity of mental health symptoms: BAI, BDI, BHS, GAF 
Clinician-completed: 
i)Severity of mental health symptoms: PANNS 
ii)Functioning: QLS, SOFAS 
Correlations between EQ-5D index and three symptom measures (BAI, BDI, 
BHS) were moderate to very strong (r=0.360-0.656) 
Correlation between EQ-5D and GAF weak but significant (0.263). 
Non significant and weak correlations with PANSS, QLS, and SOFAS 
Scalone, 2008(15) Correlations between EQ-5D and symptom and functional 
measures: 
 
Clinician-completed: 
i)Symptom PANSS, CGI-S 
ii)Functional GAF 
Weak to moderate correlations between EQ-5D and symptom measures 
(PANSS and CGI-S), range 0.189-0.393 
Studies from update search 
Pitkänen, 2011(3) Correlations between EQ-5D index, and EQ-5D health 
dimensions and Q-LES-Q items  
Item correlations ranged from 0.28 to 0.47 (all except mobility greater than 
0.30) 
 Correlation between overall index scores ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶco-efficient shows moderate correlation, r=0.455; 
p<0.001 
* Note, this is as reported in Papaioannou et al.,[Papaioannou 2011] and as categorised in the original study[Konig 2007] but might also be considered to be responsiveness 
(effect sizes). 
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Table A5: Construct validity results (known groups) for schizophrenia, adapted from Pappaionnou et al 2011. [Pappaioannou 2011] 
Author, year Method of measuring construct validity (e.g. known 
groups) 
Construct validity results 
 ?EĂŶǇƐƵďũĞĐƚŝǀĞĚĞĐŝƐŝŽŶƐŽĨ ?ƐƚƌĞŶŐƚŚ ?ĂƌĞĂƐƌĞƉŽƌƚĞĚŝŶWĂƉƉĂŝŽŶŶŽƵ ? 
Barton, 2009(5) Known groups: clinically significant differences in EQ-5D 
index scores (defined as >0.03) according to disease 
severity groups measured by: 
 
Patient completed: 
i)Severity of mental health symptoms: BAI, BDI, BHS, GAF 
Clinician-completed: 
i)Severity of mental health symptoms: PANNS 
ii)Functioning: QLS, SOFAS 
Minimally important clinical difference (MID) (>0.03) between those with 
milder and more severe scores on seven of the symptom and functioning 
measures, including PANSS, Hamilton depression rating scale, and GAF. 
Studies from update search   
Pitkänen, 2012(3) <ŶŽǁŶŐƌŽƵƉƐ PĂ ?ƐƉůŝƚďǇ ? ?A?'&Žƌ'&AN ? ? 
Known groups: b)split by ICD-10 F20 vs. F21-F29 
Mean EQ-5D index compared to mean total Q-LES-Q 
EQ-5D: a) 0.64 vs. 0.89 (p<0.001), b) 0.81 vs. 0.75 (p=0.350) 
Q-LES-Q: a) 35 vs. 45 (p<0.001), b) 43 vs. 42 (p=0.354) 
Principal component for both EQ-5D and Q-LES-Q EQ-5D met criteria (Kaiser-Meyer-KůŬŝŶA䄃? ? ? ? ? ?ĂƌƚůĞƚƚ ?ƐƚĞƐƚ ?F 166, 
df=10, P<0.001) for component analysis.  
Q-LES-Q met criteria (Kaiser-Meyer-Olkin A? ? ? ? ? ? ?ĂƌƚůĞƚƚ ?ƐƚĞƐƚ ?F 1117, 
df=105, P<0.001) for component analysis.  
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Table A6: Responsiveness results for schizophrenia, adapted from Pappaionnou et al 2011. (4) 
Author, year Method of measuring responsiveness  Responsiveness results 
 ?EĂŶǇƐƵďũĞĐƚŝǀĞĚĞĐŝƐŝŽŶƐŽĨ ?ƐƚƌĞŶŐƚŚ ?ĂƌĞĂƐƌĞƉŽƌƚĞĚŝŶWĂƉƉĂŝŽŶŶŽƵ ? 
McCrone, 2009(12) EQ-5D SRMs for BPRS response groups (>25% versus 
<25%).   
Where improvement on BPRS was at least 25%, EQ-5D SRM was small in 
size (0.39). 
Where deterioration on BPRS was at least 25% or improvement on BPRS 
<25%, EQ-5D SRMs were very small (0.17 to 0.05 respectively). 
Van der Willige, 2005(13) Differences in EQ-5D descriptive system scores between 
baseline and follow-up: 
 
Correlations between change scores for EQ-5D vs. other 
measures: 
 
Clinician-completed: 
i)Symptom PANSS, AHRS 
ii)Functional GSDS 
iii)Quality of life-generic WHOQOL-BREF 
Statistically significant differences for daily functioning (Z=1.79, p>0.05 
<0.10), and anxiety and depression (Z=3.53, p<0.001) 
Moderate correlations between changes on EQ-5D VAS and changes in 
PANSS (0.34-0.47, p>0.01 and p<0.0005). 
Correlations between changes on EQ-5D index and changes in PANSS 
existed only on PANSS positive symptoms subscale (0.53, p<0.0001). 
Moderate to strong correlations with 3 of 4 AHRS subscales and the EQ-5D 
VAS (0.46-0.50, p<0.001) 
Barton, 2009(5) Mean difference in EQ-5D score for improvers vs non 
improvers (based on improvement on 6 of 7 symptom or 
functioning measures). MID 0.03.  
Patient completed: 
i)Severity of mental health symptoms: BAI, BDI, BHS, GAF 
Clinician-completed: 
i)Severity of mental health symptoms: PANNS 
ii)Functioning: QLS, SOFAS 
Difference in mean EQ-5D scores between improvers and non-improvers 
(categorised as improvement on 6 out of 7 clinical measures) was equal to 
or greater than the MID (0.03)  
Badia, 1999(16) Effects sizes by treatment groups for EQ-VAS and EQ-5D 
index. Olanzapine versus other antipsychotics: 
risperodone, haloperidol or other). 
Large effect sizes for olanzapine-treated patients pre- and post-treatment  
EQ-5D index: 1.13  
Moderate to large effect sizes for other antipsychotics: 
EQ-5D index: 0.78 to 0.96) 
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Table A7: Rasch analysis results for schizophrenia 
Author, 
year 
Method of measuring validity Results 
 ?EĂŶǇƐƵďũĞĐƚŝǀĞĚĞĐŝƐŝŽŶƐŽĨ ?ƐƚƌĞŶŐƚŚ ?ĂƌĞĂƐƌĞƉŽƌƚĞĚŝŶWĂƉƉĂŝŽŶŶŽƵ ? 
Stochl 
2013(6) 
Item response modelling by PCM and 
GPCM, using maximum likelihood 
estimation. 
All items discriminate equally well. Akaike information criterion slightly preferred GPCM (AIC= 5,265) over PCM (AIC= 
5,269). Bayesian information criterion supported PCM (BIC=5,321) over GPCM (BIC=5,336). BIC is preferred in this 
instance as it penalizes more for model complexity and is more suitable for descriptive purposes.  
 RSM Likelihood ratio test between RSM and OCM was non-significant (likelihood difference = 3.8, df=4, p=0.43). Global fit 
indices favoured RSM (PCM: AIC = 5,249.3, BIC = 5,292.1; RSM: AIC = 5,248.9, BIC = 5,272.7). Some evidence of over-
fit, indicating items overlap, but no remedial action recommended.  
 Item-person map of RSM Items are well spaced along the intended latent measurement continuum. This confirms that EQ-5D can discriminate 
at all levels of HRQoL, regardless of the status of the patient. 
 Rasch estimates of HRQoL and 
corresponding standard errors 
Standard errors of measurement are quite large for reliable placement of any individual on the HRQoL latent 
continuum. Even less information (and thus less measurement precision) is available for people reporting lack of 
problems with any of the EQ-5D dimensions and for people with nearly maximal sum scores. EQ-5D is therefore more 
suitable for group comparisons or profiling of improvement over time for groups of patients 
rather than for individual psychiatric assessment of HRQoL. 
 Relationship between EQ-5D and 
diagnosis (expect no relationship as 
EQ-5D is not a diagnostic measure) 
4-class model (latent class analysis) best fits data. The chi-squared shows a significant (p = 0.03) relationship between 
diagnosis and EQ-5D latent class summaries of HRQoL profiles; a higher proportion of patients suffering from major 
depressive disorder and schizoaffective disorder belonged to class 3 ? the most [HRQoL] impaired class ? in 
comparison with other latent classes and diagnostic categories. This was due to the anxiety/depression item, which 
has a direct relationship to one of the main symptoms of schizophrenia. Removal of anxiety/depression item saw the 
chi-squared become non-significant (p=0.27) 
 Differential item functioning No DIF for gender or diagnosis. DIF for ethnicity, indicating EQ-5D may vary across patients with different ethnic 
minority group status. Statistically significant for white patients in anxiety/depression and usual activities: more likely 
to score some or severe problems. This should be controlled for in analyses.  
PCM, partial credit model; GPCM, generalise partial credit model; AIC, Akaike information criterion; BIC, Bayesian information criterion; RSM, rating scale model;  
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Table A8: Mandatory fields collected in the schizophrenia NCA  
TRUST/HEALTH BOARD AND TEAM
a 
 E^ƉĂƚŝĞŶƚ/ ?/ŶŝƚŝĂůŽĨĚĂƚĂĐŽůůĞĐƚŽƌ ?ĐůŝŶŝĐŝĂŶ ?ůŝŶŝĐĂůƚĞĂŵƌĞƐƉŽŶƐŝďůĞĨŽƌƚŚĞƉĂƚŝĞŶƚ ?ƐĐĂƌĞ ?ƐƐĞƌƚŝǀĞ
outreach team, community mental health team, crisis resolution team, Early intervention in psychosis 
team, other) 
PATIENT DETAILS
a 
 Year of birth, Sex, Ethnicity, Current ICD-10 mental health dimensions (F20, F25), How long ago was this 
diagnosis first made (between 1-2 years, up to 4 years, up to 10 years, more than 10 years)  
Wd/Ed ?^hZZEdDEd>,>d,a 
 hƐĞŬŶŽǁůĞĚŐĞŽĨƚŚĞƉĂƚŝĞŶƚƚŽƌĂƚĞƉĂƚŝĞŶƚ ?ƐĐƵƌƌĞŶƚŵĞŶƚĂůŚĞĂůƚŚ ?ŽŶĐůŽǌĂƉŝŶĞ ?ŶŽƚŽŶĐůŽǌĂƉŝŶĞ PĨƵůů
remission, partial remission with minimal symptoms and disability, partial remission with substantial 
symptoms and disability, not in remission)  
ANTIPSYCHOTIC MEDICATIONS
a 
  Is the patient currently prescribed antipsychotic medications (Y/N), Was the patient provided with 
written information (or an appropriate alternative) about the most recent antipsychotic prescribed (Y/N, 
ĚŽŶ ?ƚŬŶŽǁ ?ƉĂƚŝĞŶƚŶĞver prescribed an antipsychotic), For the most recently prescribed antipsychotic, 
was the patient involved in deciding which antipsychotic they were prescribed 
HISTORY OF PRESCRIBING FOR PATIENTS NOT IN REMISSION AND NOT CURRENTLY PRESCRIBED CLOZAPINET
a
 
  Not mandatory 
HISTORY OF PRESCRIBING FOR PATIENTS NOT IN REMISSION AND CURRENTLY BEING PRESCRIBED CLOZAPINE 
  Not mandatory 
PHYSICAL HEALTH MONITORING
a 
 Does the patient currently have any of the following significant physical health problems (and is it 
ƌĞĐŽƌĚĞĚŝŶǇŽƵƌĐĂƐĞƌĞĐŽƌĚŽƌƚŚĞ'W ?ƐƌĞĐŽƌĚƐ ? PĂƌĚŝŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞ ?ĚŝĂďĞƚĞƐ ?ŚǇƉĞƌƚĞŶƐŝŽŶ ?
dyslipidaemia 
PHYSICAL HEALTH RECORDS
 
  
Not mandatory 
PSYCHOLOGICAL THERAPIES
 
  
Has cognitive behavioural therapy EVER been offered to the patient, Has family intervention (where 
patient is in contact with family) EVER been offered to the patient 
CARE PLAN
 
  
Not mandatory 
a 
collected via the NAS audit of practice form 
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Table A9: Optional fields collected in the schizophrenia NCA (WP1.3) 
TRUST/HEALTH BOARD AND TEAM
a 
 No additional non-mandatory fields 
PATIENT DETAILS
a 
 No additional non-mandatory fields 
Wd/Ed ?^hZZEdDEd>,>d,a 
 No additional non-mandatory fields 
ANTIPSYCHOTIC MEDICATIONS
a 
  Provide current dose of all antipsychotics currently being prescribed for the patient (list), If the current 
antipsychotic dose is known to be above the BNF recommended dose, has a rationale for this been 
ĚŽĐƵŵĞŶƚĞĚŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞĐŽƌĚƐ ?/ĨƚŚĞƉĂƚŝĞŶƚŝƐĐƵƌƌĞŶƚůǇďĞŝŶŐƉƌĞƐĐƌŝďed two or more 
ĂŶƚŝƉƐǇĐŚŽƚŝĐĚƌƵŐƐĂƚƚŚĞƐĂŵĞƚŝŵĞ ?ŚĂƐĂƌĂƚŝŽŶĂůĞĨŽƌƚŚŝƐďĞĞŶĚŽĐƵŵĞŶƚĞĚŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞĐŽƌĚƐ ?
How long has the patient been on clozapine, What was the reason for starting the patient on clozapine 
(Treatment resistant/poor response, adverse effects from previous antipsychotic medication, both of the 
above, not known, other, How many antipsychotic medications was the patient prescribed before 
clozapine. 
HISTORY OF PRESCRIBING FOR PATIENTS NOT IN REMISSION AND NOT CURRENTLY PRESCRIBED CLOZAPINET
a
 
  Why is this patient not currently prescribed clozapine (not yet had adequate trial of two other 
antipsychotices, clozapine contratindicated for this patient, clozapine tried but patient did not respon 
adequately, clozapine offered but patient refused, ongoing anxiety and depression but not psychotic 
symptoms, Trust restrictions on use of clozapine, waiting for an inpatient bed, lack of facility for 
community initiation, Is the current antipsychotic the first antipsychotic medication prescribed for the 
patient, How many other antipsychotics did the patient receive before the current one, How long has the 
patient been on the current antipsychotic medication, In the past 12 months, has medication adherence 
been investigated as a potential cause of inadequate response to antipsychotic medications, In the past 
12 months, has alcohol or substance misuse been investigated as a potential cause if inadequate 
response to antipsychotic medications 
HISTORY OF PRESCRIBING FOR PATIENTS NOT IN REMISSION AND CURRENTLY BEING PRESCRIBED CLOZAPINE 
  Before starting clozapine was the patient trialled on at least two second generation antipsychotics, If the 
patient is currently prescribed clozapine plus another antipsychotic, has the patient been trialled on this 
combination for at least 8 weeks at optimal dose, In the past 12 months, has medication adherence been 
investigated as a potential cause of inadequate response to antipsychotic medications, In the past 12 
months, has alcohol or substance misuse been investigated as a potential cause if inadequate response to 
antipsychotic medications 
PHYSICAL HEALTH MONITORING
a 
 No additional non-mandatory fields 
PHYSICAL HEALTH RECORDS
 
  
Smoking status (current smoker, non smoker), Current alcohol intake, Current substance misuse, Current 
most recent BMI, Waist circumference, Current/most recent blood pressure, Current/most recent 
glucose, Current most recent cholesterol, Family history of cardiovascular disease, diabetes, 
hypertension, dyslipidaemia, Has any interventions been offered, or a referral made, within last 12 
months for any of the following: advice about diet/exercise, treatment for cardiovascular disease, 
diabetes, dyslipidaemia or hypertension, Help with: smoking cessation, reducing alcohol consumption or 
reducing substance misuse. What was the source of the information used to answer questions (case 
record and psychiatrist knowledge, case record, psychiatric knowledge and GP, GP only, other) 
PSYCHOLOGICAL THERAPIES
 
  
If psychological therapy offered, was this taken up by the patient (CBT or family intervention: yes, no 
patient refuse, no reason not recorded, do not know, other) 
CARE PLAN
 
  
Does the patient have a current care plan 
a 
collected via the NAS audit of practice form, CBT: Cognitive based therapy 
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Table A10: Non-mandatory fields collected in the schizophrenia NCA (2) (WP1.3) 
SERVICE USER: questions relate to experiences within the previous 12 months (Anonymous) 
THE QUALITY OF CARE YOU RECEIVED
a 
 Are you satisfied with the times and places of your appointments, Are you satisfied with the amount of 
time available for talking with members of the service about your problems, Do you feel confident that 
members of the service are competent in dealing with your problems, Taking everything into 
consideration, are you pleased with the care you have received for the service so far, How satisfied were 
you with the service you received at your GP surgery during the last 12 months. 
GETTING HELP FROM PEOPLE YOU KNOW WHEN YOU NEED IT
a 
 Do you have a key worker or care coordinator, Do you know how to contact your key worker or care 
coordinator, How satisfied are you with your access to your key worker or care coordinator, Has there 
been a change in your key worker or care coordinator in the last year, Has there been a change in your 
psychiatrist in the last year, Do you know how to get help for your mental health if there is a crisis or 
emergency and you need help right away, Do you have a care plan that provides you and other people 
with information about what your main mental health issues are and what help you are getting with 
these, Do you have an advance directive that provides you and other people with information about what 
you would like to happen should you become unwell 
MEDICATION
a 
 Was the purpose of the current medication for your mental health explained to you, including what could 
happen if you stopped taking it, Were the side effects of the medication discussed with you, Were your 
views taken into account when deciding which medication to prescribe, Were you given written or online 
information about your medication 
YOUR PHYSICAL HEALTH
a 
 Has your weight been checked by a nurse or doctor in the last 12 months, Has your blood pressure been 
checked by a nurse or doctor in the last 12 months, Has your blood pressure been checked by a nurse or 
doctor in the last 12 months, Have you had blood tests carried out in the last 12 months, In relation to 
smoking cigarettes (I smoke and am getting help to stop; I smoke and am not getting help to stop; I 
smoke and do not want help to stop; I do not smoke) 
OTHER TYPES OF TREATMENT AND HELP
a
 
  In relation to work and employment (I do not have a job but am getting help to find one, I do not have a 
job and am not getting help to find one, I do not have a job and am not looking for one, I have job), In 
relation to other activities: I am involved in activities during my day (e.g. education, drop-in group) etc, In 
relation to Cognitive behavioural therapy (I have had or am receiving this treatment, I have not had this 
treatment, I do not want this treatment), In relation to family intervention/therapy (I have had or am 
receiving this treatment, I have not had this treatment, I do not want this treatment) 
OVERALL 
  To what extent have services helped you to achieve good mental health in last year (helped a lot, helped 
a little, made no difference, made me worse) 
CARER SURVEY (questions relate to experiences within the previous 12 months (Anonymous)
b 
 Information and advice for carers: Enough information about the condition/illness of the person you care 
for to enable you to feel confident in caring for them, enough information about how their 
condition/illness is likely to develop in the longer term? that you can get whatever information you need 
when you need it (e.g. through your doctor or on your own)? with how easy it is to understand the 
information you have? with the amount of advice available to you (e.g. from healthcare workers or other 
carers) that you are clear about who to go to for the information and advice you need? that you are clear 
about who to contact if there is an emergency and you need help right away? that you are clear about 
who to call if you have a routine enquiry, Your involvement in treatment and care planning: In general, 
how satisfied were you with: important decisions (e.g. medication or hospitalisation, Ability to influence 
important decisions. 
Support from medical and/or care staff: In general, how satisfied were you with: how easy it was to get 
help and support from staff for the person you care for (e.g. to prevent relapse)? how easy it was to get 
help and support from staff for yourself (e.g. advice on how to deal with certain behaviours)? the quality 
of help and support from staff for the person you care for? Your relationships with key staff who support 
the person you care for, How well the staff are communicating with each other (i.e. that they share 
important information), How seriously staff take what you say to them, the level of understanding staff 
have of what it must be like to be in your situation. 
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CARER SURVEY (Background information)
 
  
Year of birth, Gender, Ethnic background, Employment status, In what year did you first start caring for 
someone with a mental health problem, Estimate how many hours you spent in the last week looking 
after someone with a mental health problem, Was this: more hours than usual, about the same number 
of hours as usual, fewer hours than usual, Who is the person whom you care for in relation to you 
(son/daughter, partner, brother/sister, parent, friend, other, Do you live with each other at the moment, 
If no, where are they currently living, Which of the following statements best describes your role as a 
carer at the moment: I am the only caregiver, I share caring responsibilities with others, but a I am the 
main caregiver, I share caring responsibilities with others, I share caring responsibilities, but someone 
else is the main caregiver, Other, How many people with mental health problems do you currently care 
for 
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Table A11. Reports of other measures in schizophrenia (WP1.2) 
Source, 
date 
Population Method used to reach recommendation Measures 
recommended 
Implementation 
issues for large 
scale use? 
  General 
methods 
Psychometric 
properties 
considered? 
Measures 
considered 
  
Royal 
College of 
Psychiatrists 
guideline: 
adults 
2012(18) 
Adult 
psychiatry 
(section on 
psychotic 
disorders) 
Methods not 
described. 
Unclear Unclear BPRS  W 24 
symptom 
constructs to 
be rated on 7-
point scale 
PANSS  W 
interview (45-
50 mins), 
clinician rated 
KGV  W 
interview 
covering 14 
symptoms, 
clinician rated 
SSPI  W 20 item 
Most appear to 
be clinician-
rated, and 
involve an 
interview. 
Royal 
College of 
Psychiatrists 
guideline: 
older 
adults(19) 
Older 
adults 
Authored by 
a working 
group 
Unclear Unclear BPRS  W 24 
symptom 
constructs to 
be rated on 7-
point scale 
PANSS  W 
interview (45-
50 mins), 
clinician rated 
 
Clinician-rated, 
and involve an 
interview. 
EMA 
research 
guideline 
2012(20) 
Adults, 
paediatrics, 
adolescents 
Expert panel 
and 
stakeholder 
consultation: 
Efficacy 
working 
party of 
committee 
for medicinal 
products for 
human use 
(CHMP) 
Unclear Unclear PANSS and 
BPRS 
considered to 
be reliable and 
validated. 
Other recent 
measures 
acceptable if 
referenced to 
PANSS and 
BPRS. 
 
Secondary 
outcomes 
should be 
recorded, and 
use CGI 
All measures are 
clinician-rated 
and involve an 
interview 
BPRS, brief psychiatric rating scale; PANSS, positive and negative syndrome scale; KGV, Krawiecka, Goldberg 
and Vaughan Scale; SSPI, signs and symptoms of psychotic illness; CGI, clinical global impression 
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